◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksS › SVNS

Solvonis Therapeutics plc (SVNS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

Solvonis Therapeutics plc (SVNS) operates in the Biotechnology industry and is headquartered in London, United Kingdom with about 6 employees. Its market capitalization is roughly £10 million. In the fiscal year ended 2025-12-31, SVNS reported £0M in revenue and (£6M) in net income.

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders.

Interactive charts & full statements →

SVNS Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue£0M£0M£1M£0M
Gross Profit£0M£0M£0M
Operating Income (EBIT)(£4M)(£2M)(£2M)(£3M)
Net Income(£6M)(£2M)(£3M)(£3M)

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVNS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2024-12-31
Total Revenue£0M
Gross Profit£0M
Operating Income (EBIT)(£0M)
Net Income(£0M)

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVNS Free Cash Flow History

SVNS Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets£8M£3M£2M£5M
Total Liabilities£1M£0M£0M£0M

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SVNS viewer.

Other Companies in Biotechnology

← SVMAll “S” companiesSVRA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.